The role of Wobe-Mugos in reducing acute sequele of radiation in head and neck cancers--a clinical phase-III randomized trial

Indian J Cancer. Jun-Dec 1999;36(2-4):141-8.

Abstract

Oral enzymes act as a potent antiinflammatory, antiedematous agents thereby decreasing acute toxigenic effect of radiation and increasing compliance, quality of life of our patients. Fifty patients were randomized 25 allocated in enzyme and radiotherapy arm, 25 in radiotherapy alone. Pre RT and post RT biopsies were taken from both arms. In our study it was found that there was clinical, histopathological as well as statistical significant difference in both arms. The enzyme arm patients had mucostis of grade I in 76%, grade II in 12%, grade III in 8% while as 8% had grade I, 68% grade II, 24% had grade III in RT arm alone. In enzyme patients skin reactions of grade I in 72%, 20% had grade II, 8% had grade III. In control arm 12% had grade I, 76% had grade II, 8% had grade III skin reaction.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / therapeutic use*
  • Administration, Oral
  • Adult
  • Carcinoma, Squamous Cell / radiotherapy*
  • Chymotrypsin*
  • Drug Combinations
  • Head and Neck Neoplasms / radiotherapy*
  • Humans
  • Middle Aged
  • Mouth Mucosa / radiation effects
  • Pancreatic Extracts / administration & dosage
  • Pancreatic Extracts / therapeutic use*
  • Papain / administration & dosage
  • Papain / therapeutic use*
  • Prospective Studies
  • Radiodermatitis / prevention & control*
  • Thymus Extracts / administration & dosage
  • Thymus Extracts / therapeutic use*
  • Trypsin*

Substances

  • Adjuvants, Immunologic
  • Drug Combinations
  • Pancreatic Extracts
  • Thymus Extracts
  • chymotrypsin, papain, trypsin drug combination
  • Chymotrypsin
  • Trypsin
  • Papain